Locations:
Abu Dhabi|Canada|Florida|London|Nevada|Ohio|
Gray gradientGray gradient
Cleveland Clinic icon
Consult QD logo
Search IconSearch

Tag: multiple sclerosis (MS)

20-NEU-1873707-multiple-sclerosis-brain-sample-650×450

What We’re Learning from the Brains and Spinal Cords of People with MS (Podcast)

Bruce Trapp, PhD, reflects on decades of basic and translational research

20-NEU-1882508_CQD_650x450_combined

Thalamus Is a Prime Target for Neurodegeneration in MS, Study Suggests

Researchers pair postmortem MRI with histopathology to explore thalamic atrophy

COVID-19 hero-650×450
April 27, 2020/COVID-19

Managing Multiple Sclerosis During the COVID-19 Pandemic

What to do with what we know, and how we’re gathering more data

Virtual yoga class
April 8, 2020/Behavioral Health

In the Wake of COVID-19, Taking a Mind-Body Approach to Chronic Neurological Disease Matters More Than Ever

Virtual visits enable continued stress management and wellness care for MS patients

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Covid image 650×450
March 18, 2020/COVID-19

How to Counsel MS Patients on Disease-Modifying Therapy About COVID-19

In general, interrupting therapy is not advised, and patients should remain in contact with their provider teams

19-NEU-6534-Cohen-stem-cells-for-MS_Hero_650x450
January 17, 2020/Cancer

New BEAT-MS Trial Stages Direct Comparison of Stem Cells and Biologics for Relapsing MS

Knocking out, then restoring, the immune system holds great promise

Bethoux, MD

Adopting New Technologies for Multiple Sclerosis Rehabilitation (Podcast)

A veteran clinician shares insights on the care-enhancing qualities of tech

nine-hole peg test on an ipad

Realizing Next-Generation Motor Assessment Through Massive Tech-Enabled Data Capture

Important progress toward predictive analytics in MS and PD

19-NEU-3979-relapsing-multiple-sclerosis-650×450
September 24, 2019/Neurosciences/Research

Phase 3 Ozanimod Trials Show Good Efficacy and Tolerability at 2 Years for Relapsing MS

Findings hint at potentially easier treatment initiation vs. other S1P receptor modulators

19-NEU-3973-vaccineMS-grant-650×450
September 19, 2019/Neurosciences/News & Insights

AAN Updates Its Guideline on Vaccines in Multiple Sclerosis: What Providers Need to Know

Recommendations revisited in wake of a surge in disease-modifying therapies

BackPage 6 of 9Next

Advertisement

Ad